Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 6Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other hematologic neoplasm 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Colorectal Neoplasms 13Colonic Neoplasms 11Pancreatic Neoplasms 10Rectal Neoplasms 7Stomach Neoplasms 6Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Small Cell Lung Carcinoma 5Carcinoma, Renal Cell 5Ovarian Neoplasms 4Kidney Neoplasms 4Carcinoma, Hepatocellular 4Astrocytoma 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Melanoma 2Liver Neoplasms 2Gallbladder Neoplasms 2Familial ependymoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × sargramostim × Gastrointestinal × Clear all
NCT05269381 2026-03-12

PNeoVCA

Mayo Clinic

Phase 1/2 Recruiting
132 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡